Retatrutide, a novel dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising results in early clinical studies. Ongoing examination https://cyberbookmarking.com/story21288333/retatrutide-emerging-studies-and-possible-clinical-uses